BPC-157 vs Sigumir
Comparison of BPC-157 (Low evidence) and Sigumir (Low evidence).
Last updated: February 12, 2026
BPC-157
Sigumir
Overview
BPC-157 and Sigumir are both studied in the peptide research space.
BPC-157: A synthetic peptide derived from human gastric juice protein.
Sigumir: A cytamin-class peptide supplement derived from cartilage tissue, part of the Russian bioregulator framework.
Evidence Comparison
| Aspect | BPC-157 | Sigumir |
|---|---|---|
| Evidence Level | Low | Low |
| Human Studies | 3 | 1 |
| Preclinical Studies | 29 | 5 |
| Total Sources | 32 | 7 |
Key Differences
| Aspect | BPC-157 | Sigumir |
|---|---|---|
| Category | Repair & Recovery | Repair & Recovery |
| Evidence Strength | Low | Low |
| Total Sources | 32 | 7 |
| Human Studies | 3 | 1 |
Summary
- BPC-157: Low evidence with 32 total sources (3 human)
- Sigumir: Low evidence with 7 total sources (1 human)
This comparison is for educational purposes only and is not medical advice. Consult a healthcare professional before making any decisions about peptide use.
View Full Dossiers
Stay Updated on Peptide Comparisons
Get notified when we publish new comparison dossiers and evidence reviews.
No spam. Unsubscribe anytime.
Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual responses to medications vary. Always consult a qualified healthcare provider before making treatment decisions.